SciSparc (SPRC) Competitors $0.28 +0.01 (+2.30%) As of 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRC vs. TXMD, BGXX, AFMD, NERV, RLYB, RLMD, PHXM, IXHL, GOVX, and NXTCShould you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include TherapeuticsMD (TXMD), Bright Green (BGXX), Affimed (AFMD), Minerva Neurosciences (NERV), Rallybio (RLYB), Relmada Therapeutics (RLMD), PHAXIAM Therapeutics (PHXM), Incannex Healthcare (IXHL), GeoVax Labs (GOVX), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry. SciSparc vs. TherapeuticsMD Bright Green Affimed Minerva Neurosciences Rallybio Relmada Therapeutics PHAXIAM Therapeutics Incannex Healthcare GeoVax Labs NextCure TherapeuticsMD (NASDAQ:TXMD) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Do insiders and institutionals believe in TXMD or SPRC? 30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 2.3% of TherapeuticsMD shares are owned by insiders. Comparatively, 1.5% of SciSparc shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor TXMD or SPRC? TherapeuticsMD received 384 more outperform votes than SciSparc when rated by MarketBeat users. However, 66.67% of users gave SciSparc an outperform vote while only 58.13% of users gave TherapeuticsMD an outperform vote. CompanyUnderperformOutperformTherapeuticsMDOutperform Votes38658.13% Underperform Votes27841.87% SciSparcOutperform Votes266.67% Underperform Votes133.33% Which has preferable valuation & earnings, TXMD or SPRC? SciSparc has lower revenue, but higher earnings than TherapeuticsMD. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTherapeuticsMD$1.76M9.17-$10.28MN/AN/ASciSparc$1.75M1.74-$5.12MN/AN/A Which has more volatility and risk, TXMD or SPRC? TherapeuticsMD has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, SciSparc has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Is TXMD or SPRC more profitable? SciSparc has a net margin of 0.00% compared to TherapeuticsMD's net margin of -207.77%. SciSparc's return on equity of 0.00% beat TherapeuticsMD's return on equity.Company Net Margins Return on Equity Return on Assets TherapeuticsMD-207.77% -14.08% -9.61% SciSparc N/A N/A N/A Does the media refer more to TXMD or SPRC? In the previous week, SciSparc had 4 more articles in the media than TherapeuticsMD. MarketBeat recorded 6 mentions for SciSparc and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.94 beat SciSparc's score of 0.20 indicating that TherapeuticsMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SciSparc 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTherapeuticsMD beats SciSparc on 7 of the 13 factors compared between the two stocks. Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRC vs. The Competition Export to ExcelMetricSciSparcPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.03M$6.74B$5.50B$7.98BDividend YieldN/A3.05%5.11%4.23%P/E RatioN/A7.3622.6318.59Price / Sales1.74242.40398.09103.52Price / CashN/A65.8538.1834.62Price / Book0.026.506.724.27Net Income-$5.12M$143.41M$3.22B$248.18M7 Day Performance-4.08%2.04%1.58%1.47%1 Month Performance-0.32%6.96%4.09%3.96%1 Year Performance-79.56%-2.51%16.05%5.57% SciSparc Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRCSciSparc0.9616 of 5 stars$0.28+2.3%N/A-80.5%$3.03M$1.75M0.004Short Interest ↓Positive NewsTXMDTherapeuticsMD1.7627 of 5 stars$1.00-1.4%N/A-34.0%$11.53M$1.76M0.00420Analyst ForecastBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownAFMDAffimed3.5165 of 5 stars$0.70-4.0%$13.50+1,818.2%-81.4%$11.33M$877,000.000.00200NERVMinerva Neurosciences3.7992 of 5 stars$1.66+3.8%$5.00+201.2%-29.2%$11.19MN/A-3.779Negative NewsRLYBRallybio2.3249 of 5 stars$0.27+6.0%$10.00+3,672.2%-83.3%$11.03M$636,000.00-0.1740Upcoming EarningsGap UpRLMDRelmada Therapeutics4.3497 of 5 stars$0.32+11.5%$4.25+1,215.8%-91.1%$10.72MN/A-0.1110Upcoming EarningsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049IXHLIncannex Healthcare0.6312 of 5 stars$0.59-1.7%N/A-94.9%$10.54M$98,000.00-0.423Short Interest ↑GOVXGeoVax Labs2.7814 of 5 stars$0.76-8.4%$12.90+1,597.1%-27.9%$10.52M$3.95M-0.1310NXTCNextCure4.6485 of 5 stars$0.37+2.2%$3.50+848.5%-61.5%$10.35MN/A-0.1890Short Interest ↓Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies TXMD Alternatives BGXX Alternatives AFMD Alternatives NERV Alternatives RLYB Alternatives RLMD Alternatives PHXM Alternatives IXHL Alternatives GOVX Alternatives NXTC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
